Page 94 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

As Incoming CEO, Dr Crystal Denlinger Highlights NCCN Guidelines, Challenges, and Treatment Access

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments. ....

National Comprehensive Cancer Network , Crystal Denlinger , Patient Access ,

2 Minute Medicine Rewind August 21, 2023 | 2 Minute Medicine

Women’s Adherence to Healthy Dietary Patterns and Outcomes of Infertility Treatment | Obstetrics and Gynecology 1. For women with infertility on assisted reproductive technologies (ART), higher preconception adherence to dietary patterns for prevention of chronic disease were associated with lower probability of pregnancy loss, but no difference for clinical pregnancy or live birth. Evidence Rating ....

United States , United Kingdom , American Heart Association , European Point Prevalence Survey Of Infections , International Nuclear Workers Study , Rating Level , Healthy Eating Index , Alternate Healthy Eating Index , Appropriateness Evaluation Protocol , Harvard Medical Practice Study , European Point Prevalence Survey , Healthcare Associated Infections , Weekly Rewinds ,

Endocrine therapy and breast-conserving surgical management without follow-up radiotherapy is safe in low-risk, luminal A subtype breast cancer

1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years without radiotherapy was 97.2%, with a disease-free survival rate of 89.9%. Evidence Rating Level: 1 (Excellent) Study Rundown: After breast-conserving surgical management of breast cancer, radiotherapy is often provided to help prevent recurrence, but not without inconvenience, increased risk of side ....

Minute Medicine Inc , Rating Level , Breast Cancer , Luminal A , Chronic Disease ,

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo group, with HR 0.39. 2. Adverse events (grade 3 and above) that were more common with vorasidenib than with placebo were an elevated alanine aminotransferase level, an elevated aspartate aminotransferase level, and an increased γ-glutamyltransferase ....

Rating Level , Brain Penetrant Dual Inhibitor , Idh 2 Mutated , Idh1 Mutated , Chronic Disease ,

Kazakh capital to host 1st Central Asian Oncology Week

ASTANA. KAZINFORM The Kazakh capital will play a host to the first-ever international scientific conference Central Asian Oncology Week on September 6-8, Kazinform cites the Kazakh Healthcare Ministry’s press service. ....

Gorod Astana , United Kingdom , South Korea , Kazakh Healthcare Ministry , Society Of Surgical Oncologists , National Scientific Oncology Centre , Central Asian Oncology Week , Central Asia , Surgical Oncologists , Kazakh Healthcare ,